# Clinical trial results:
# Bictegravir concentrations and antiviral activity in cerebrospinal fluid in HIV-1 Infected individuals

## Summary

| | |
|---|---|
| EudraCT number | 2018-000302-39 |
| Trial protocol | ES |
| Global end of trial date | 25 September 2018 |

### Results information

| | |
|---|---|
| Result version number | v1 (current) |
| This version publication date | 17 October 2021 |
| First version publication date | 17 October 2021 |

## Trial information

### Trial identification

| | |
|---|---|
| Sponsor protocol code | IN-ES-380-4475 |

### Additional study identifiers

| | |
|---|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN) | - |

Notes:

### Sponsors

| | |
|---|---|
| Sponsor organisation name | Fight AIDS and Infectious diseases foundation |
| Sponsor organisation address | Cta de Canyet s/n, Badalona, Spain, |
| Public contact | Albert Tuldrà, Fight AIDS and Infectious diseases foundation, 0034 934657897, atuldra@flsida.org |
| Scientific contact | Albert Tuldrà, Fight AIDS and Infectious diseases foundation, 0034 934657897, atuldra@flsida.org |

Notes:

### Paediatric regulatory details

| | |
|---|---|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

| | |
|---|---|
| Analysis stage | Final |
| Date of interim/final analysis | 05 November 2018 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 25 September 2018 |
| Global end of trial reached? | Yes |
| Global end of trial date | 25 September 2018 |
| Was the trial ended prematurely? | No |

Notes:

## General information about the trial

Main objective of the trial:

- To assess Bictegravir concentrations in CSF and to estimate penetration into the CNS.
-To evaluate antiviral activity of a combination of TAF/FTC/BIC in CSF.

Protection of trial subjects:

The sponsor contracted an insurance as a mandatory aspect defined in the legal framework of the country site due a different procedures performed during the clinical trial out of routine clinical practice.

Background therapy: -

Evidence for comparator: -

| | |
|---|---|
| Actual start date of recruitment | 09 April 2018 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

## Population of trial subjects

### Subjects enrolled per country

| | |
|---|---|
| Country: Number of subjects enrolled | Spain: 15 |
| Worldwide total number of subjects | 15 |
| EEA total number of subjects | 15 |

Notes:

### Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 15 |
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

## Subject disposition

### Recruitment

Recruitment details:

Subjects who met inclusion criteria and accepted to sign the informed consent to participate will be cited for a screening visit. A total of 16 HIV-infected patients were selected at the screening phase. Recruitment started on 23/Jul/2018, last patient recurited was on 31/Jul/2018.

### Pre-assignment

Screening details:

16 patients were screened. One patient didn't meet all inclusion criteria

### Pre-assignment period milestones

| | |
|---|---|
| Number of subjects started | 15 |
| Number of subjects completed | 15 |

### Period 1

| | |
|---|---|
| Period 1 title | Overall trial (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Not applicable |
| Blinding used | Not blinded |

### Arms

| | |
|---|---|
| **Arm title** | BIC/TAF/FTC |

Arm description:

Bictegravir/Emtricitabine/Tenofovir alafenamide fumarate

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | Bictegravir/Emtricitabine/Tenofovir alafenamide fumarate |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

50 mg of Bictegravir/ 200 mg of Emtricitabine/25 mg of Tenofovir alafenamide fumarate

| **Number of subjects in period 1** | BIC/TAF/FTC |
|---|---|
| Started | 15 |
| Completed | 15 |

## Baseline characteristics

### Reporting groups

| Reporting group title | Overall trial (overall period) |
|---|---|

Reporting group description: -

| Reporting group values | Overall trial (overall period) | Total | |
|---|---|---|---|
| Number of subjects | 15 | 15 | |
| Age categorical<br>Units: Subjects | | | |
| In utero | | 0 | |
| Preterm newborn infants (gestational age < 37 wks) | | 0 | |
| Newborns (0-27 days) | | 0 | |
| Infants and toddlers (28 days-23 months) | | 0 | |
| Children (2-11 years) | | 0 | |
| Adolescents (12-17 years) | | 0 | |
| Adults (18-64 years) | | 0 | |
| From 65-84 years | | 0 | |
| 85 years and over | | 0 | |
| Age continuous<br>Units: years | | | |
| median | 42 | | |
| inter-quartile range (Q1-Q3) | 37 to 56 | - | |
| Gender categorical<br>Units: Subjects | | | |
| Female | 2 | 2 | |
| Male | 13 | 13 | |

## End points

### End points reporting groups

| | |
|---|---|
| Reporting group title | BIC/TAF/FTC |
| Reporting group description: | |
| Bictegravir/Emtricitabine/Tenofovir alafenamide fumarate | |

### Primary: Total Bictegravir concentrations in cerebrospinal fluid.

| | |
|---|---|
| End point title | Total Bictegravir concentrations in cerebrospinal fluid.[1] |
| End point description: | |
| | |
| End point type | Primary |
| End point timeframe: | |
| w12 | |

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Data reported has been a descriptive analysis, which shows the total Bictegravir concentration in CSF

| End point values | BIC/TAF/FTC | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 15 | | | |
| Units: ng/ml | | | | |
| median (inter-quartile range (Q1-Q3)) | 6.9 (4.8 to 10.9) | | | |

### Statistical analyses

No statistical analyses for this end point

### Primary: Unbound Bictegravir concentrations in cerebrospinal fluid.

| | |
|---|---|
| End point title | Unbound Bictegravir concentrations in cerebrospinal fluid.[2] |
| End point description: | |
| | |
| End point type | Primary |
| End point timeframe: | |
| w12 | |

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Data reported has been a descriptive analysis, which shows the unbound Bictegravir concentration in CSF

| End point values | BIC/TAF/FTC | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 15 | | | |
| Units: ng/ml | | | | |
| median (inter-quartile range (Q1-Q3)) | 2.48 (1.6 to 3.7) | | | |

## Statistical analyses

No statistical analyses for this end point

## Primary: Total Bictegravir concentrations in blood plasma

| End point title | Total Bictegravir concentrations in blood plasma[3] |
|---|---|

End point description:

| End point type | Primary |
|---|---|

End point timeframe:

w12

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Data reported has been a descriptive analysis, which shows the total Bictegravir concentration in blood plasma

| End point values | BIC/TAF/FTC | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 15 | | | |
| Units: ng/ml | | | | |
| median (inter-quartile range (Q1-Q3)) | 1837.1 (1237.2 to 2586.7) | | | |

## Statistical analyses

No statistical analyses for this end point

## Primary: Bictegravir CSF/plasma ratio

| End point title | Bictegravir CSF/plasma ratio[4] |
|---|---|

End point description:

| End point type | Primary |
|---|---|

End point timeframe:

w12

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Data reported has been a descriptive analysis, which shows the Bictegravi-CSF/blood plasma ratio

| End point values | BIC/TAF/FTC | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 15 | | | |
| Units: Ratio | | | | |
| median (inter-quartile range (Q1-Q3)) | 0.003 (0.002 to 0.004) | | | |

## Statistical analyses

No statistical analyses for this end point

## Primary: CSF HIV-1 RNA copies

| End point title | CSF HIV-1 RNA copies[5] |
|---|---|

End point description:

| End point type | Primary |
|---|---|

End point timeframe:

w12

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Data reported has been a descriptive analysis, which shows the HIV-1 viral load in CSF

| End point values | BIC/TAF/FTC | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 15 | | | |
| Units: copies/ml | 39 | | | |

## Statistical analyses

No statistical analyses for this end point

## Primary: HIV-1 RNA in blood plasma.

| End point title | HIV-1 RNA in blood plasma.[6] |
|---|---|

End point description:

| End point type | Primary |
|---|---|

End point timeframe:

w12

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Data reported has been a descriptive analysis, which shows the HIV-1 viral load in blood plasma

| End point values | BIC/TAF/FTC | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 15 | | | |
| Units: copies/ml | 39 | | | |

## Statistical analyses

No statistical analyses for this end point

## Adverse events

| Adverse events information[1] | |
|---|---|
| Timeframe for reporting adverse events: w12 | |
| Assessment type | Systematic |

| Dictionary used | |
|---|---|
| Dictionary name | MedDRA |
| Dictionary version | 22.1 |

Frequency threshold for reporting non-serious adverse events: 1 %

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.
Justification: Non-serious adverse events were reported

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported

### Online references

http://www.ncbi.nlm.nih.gov/pubmed/31784745